Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 6,049,045 shares, a growth of 117.4% from the February 12th total of 2,782,461 shares. Based on an average daily trading volume, of 3,806,703 shares, the short-interest ratio is currently 1.6 days. Approximately 0.1% of the shares of the company are sold short. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 3,806,703 shares, the short-interest ratio is currently 1.6 days.
Analyst Ratings Changes
Several equities analysts have recently issued reports on RHHBY shares. Barclays raised shares of Roche from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Zacks Research raised shares of Roche from a “strong sell” rating to a “hold” rating in a report on Monday, January 5th. Morgan Stanley reiterated an “underweight” rating on shares of Roche in a research report on Wednesday, February 4th. HSBC reissued a “buy” rating and set a $57.00 target price on shares of Roche in a research note on Wednesday, December 10th. Finally, TD Cowen restated a “hold” rating on shares of Roche in a research note on Tuesday, February 10th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Roche presently has a consensus rating of “Hold” and an average price target of $57.00.
Get Our Latest Report on RHHBY
Hedge Funds Weigh In On Roche
Roche Trading Down 1.4%
Shares of OTCMKTS:RHHBY traded down $0.73 on Friday, hitting $51.20. The company’s stock had a trading volume of 409,734 shares, compared to its average volume of 2,768,175. Roche has a 12 month low of $34.75 and a 12 month high of $60.85. The stock’s 50-day moving average is $56.06 and its two-hundred day moving average is $48.93. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72.
Roche Company Profile
Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).
In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.
Read More
- Five stocks we like better than Roche
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
